IQ is seeking capital to commercialize the first photochromic contact lenses, which will allow the lenses to change opacity in response to UV light exposure. The technology is patented. The startup aims to gain a 0.5% market share in the US contact lens market within 5 years, projecting $20 million in exit value. Clinical trials will evaluate the lenses' performance.
This document provides an overview of a proposed nanobiotechnology company. It begins with definitions of nanotechnology and describes how materials can be constructed at the nanoscale using top-down or bottom-up techniques. It then outlines the company's strategy, competitive advantages, and SWOT analysis. Key aspects include outsourcing R&D to external research groups, focusing on green energy and environmental applications, and having a multidisciplinary team. The business plan also discusses the nanobiotechnology market, technology transfer, marketing mix considerations around products, pricing, promotion, and geographic expansion. The overall aim is to generate shareholder value by creating innovative nanotech solutions for environmental problems.
The document discusses the STP process of market segmentation, targeting, and positioning. It defines segmentation as classifying customers into groups, targeting as evaluating segment attractiveness and selecting segments, and positioning as arranging a product to occupy a clear place in the consumer's mind. The document then provides details on how to conduct segmentation, targeting, and positioning including identifying bases for segmentation, developing selection criteria, and choosing a market coverage strategy.
J. Joshua Sadler is seeking a mid-level managerial position with over 5 years of experience in customer service, event planning, and administration roles. He has worked for several large companies including Spring Arbor University, The Julian Krinsky Group, MGM Grand Detroit, Quicken Loans, and Volkswagen of America. Sadler has a Bachelor's degree in Psychology from Spring Arbor University and several certifications in customer service, healthcare, and mortgage loan origination.
This document discusses opportunities for Australian brands in Asia, focusing on China and Malaysia. It outlines key trends in the Asian digital landscape like rapid mobile growth and social media usage. The document emphasizes doing in-depth market research, adapting marketing strategies to local customs, localizing brands and products, and utilizing local expertise. Case studies show how brands like Adidas, Dove and Tourism Victoria successfully entered Asian markets by following these practices. The importance of hosting websites locally within China to improve the user experience is also highlighted.
GEO Medical Co., Ltd. is a leading manufacturer of contact lenses located in Gwangju, South Korea. It has steadily grown its production capabilities and quality control systems since being founded in 2002. GEO supplies innovative fashion lenses in colorful designs and tones to meet the needs of global customers. Their magic color and circle lens products provide various patterns and colors to make eyes look attractive and stylish.
Younique Cosmetics & Skin Care Catalog for September 2015 through February 2016. Place your order at www.eyeglamlashes.com or contact me with any questions! XO ~Dawn
Facial contour cosmetics are used in facial makeup to enhance or change facial features. Different types of facial contour cosmetics can be used to highlight or shade areas of the face to manipulate how facial features appear. Facial contouring cosmetics allow people to shape their facial structure through the strategic application of makeup.
Profile of Maxvue Vision, exporter of contact lenses to over 60 countries world wide. Maxvue manufacture the widest range coloured and costume contact lenses in the world. Our ColourVUE Crazy Lens is No 1 brand in the world for costume lenses segment.
Our Hydrosoft prescription contact lens deliver excellent value for money. Silicone hydrogel level performance for half the price.
Checkout the latest range of products like Maxvue soft colours , enhancement lenses and Maxvue Shades - sunglass in contact lenses.
contact us for enquiry.
info@colourvue-lens.com
This document provides an overview of a proposed nanobiotechnology company. It begins with definitions of nanotechnology and describes how materials can be constructed at the nanoscale using top-down or bottom-up techniques. It then outlines the company's strategy, competitive advantages, and SWOT analysis. Key aspects include outsourcing R&D to external research groups, focusing on green energy and environmental applications, and having a multidisciplinary team. The business plan also discusses the nanobiotechnology market, technology transfer, marketing mix considerations around products, pricing, promotion, and geographic expansion. The overall aim is to generate shareholder value by creating innovative nanotech solutions for environmental problems.
The document discusses the STP process of market segmentation, targeting, and positioning. It defines segmentation as classifying customers into groups, targeting as evaluating segment attractiveness and selecting segments, and positioning as arranging a product to occupy a clear place in the consumer's mind. The document then provides details on how to conduct segmentation, targeting, and positioning including identifying bases for segmentation, developing selection criteria, and choosing a market coverage strategy.
J. Joshua Sadler is seeking a mid-level managerial position with over 5 years of experience in customer service, event planning, and administration roles. He has worked for several large companies including Spring Arbor University, The Julian Krinsky Group, MGM Grand Detroit, Quicken Loans, and Volkswagen of America. Sadler has a Bachelor's degree in Psychology from Spring Arbor University and several certifications in customer service, healthcare, and mortgage loan origination.
This document discusses opportunities for Australian brands in Asia, focusing on China and Malaysia. It outlines key trends in the Asian digital landscape like rapid mobile growth and social media usage. The document emphasizes doing in-depth market research, adapting marketing strategies to local customs, localizing brands and products, and utilizing local expertise. Case studies show how brands like Adidas, Dove and Tourism Victoria successfully entered Asian markets by following these practices. The importance of hosting websites locally within China to improve the user experience is also highlighted.
GEO Medical Co., Ltd. is a leading manufacturer of contact lenses located in Gwangju, South Korea. It has steadily grown its production capabilities and quality control systems since being founded in 2002. GEO supplies innovative fashion lenses in colorful designs and tones to meet the needs of global customers. Their magic color and circle lens products provide various patterns and colors to make eyes look attractive and stylish.
Younique Cosmetics & Skin Care Catalog for September 2015 through February 2016. Place your order at www.eyeglamlashes.com or contact me with any questions! XO ~Dawn
Facial contour cosmetics are used in facial makeup to enhance or change facial features. Different types of facial contour cosmetics can be used to highlight or shade areas of the face to manipulate how facial features appear. Facial contouring cosmetics allow people to shape their facial structure through the strategic application of makeup.
Profile of Maxvue Vision, exporter of contact lenses to over 60 countries world wide. Maxvue manufacture the widest range coloured and costume contact lenses in the world. Our ColourVUE Crazy Lens is No 1 brand in the world for costume lenses segment.
Our Hydrosoft prescription contact lens deliver excellent value for money. Silicone hydrogel level performance for half the price.
Checkout the latest range of products like Maxvue soft colours , enhancement lenses and Maxvue Shades - sunglass in contact lenses.
contact us for enquiry.
info@colourvue-lens.com
This document provides instructions for applying makeup. It begins by explaining how makeup can highlight one's natural features and make the face more attractive. It then discusses factors to consider like skin tone, eye color, and hair color when choosing shades. Warm and cool colors are introduced. Steps are outlined for determining skin undertone and complementary colors before selecting eye, cheek, and lip colors. Specific makeup products and tools are named. Detailed instructions are given for the application process and cleanup. The goal is to choose flattering shades and apply makeup to subtly enhance one's natural beauty.
This document provides an overview of business policy and strategic management. It defines strategic management as analytical thinking and commitment of resources to action aimed at ensuring organizational objectives are achieved. The document outlines the strategic management process, including developing a corporate vision and mission, and operating strategies at different organizational levels. It also defines strategy as a long-range plan to achieve an organization's goals and position itself competitively. Finally, the document discusses how strategic management helps organizations adapt to changing business environments through strategic planning.
The document summarizes information about five French companies - ABC Texture, Agrimer, BeautyMed, Lessonia, and TechNature - exhibiting at the Beautyworld Middle East trade show. It also provides details about Bretagne Commerce International, a non-profit organization assisting Breton companies in international business. The exhibitors showcase cosmetics, natural products, and professional equipment from France's Brittany region, known for its marine resources, cosmetics industry, and support for foreign investment.
The document discusses the Global Corporate Reputation Index, which evaluates the reputations of over 6,000 companies based on consumer surveys in 6 countries. It finds that while performance scores are higher than citizenship scores, companies with strong reputations excel at both. Tech companies have the best reputations overall, while oil and gas score lowest. China has the strongest company reputations, while Japan and Brazil are most critical. Long-standing companies tend to have stronger, more durable reputations. The top 25 companies are revealed.
Glossy Make Up is a unique lash brand with a range of inspiring false lashes for makeup artists and lash-lovers. Sophisticated designs to accentuate makeup.
This document discusses different types of tinted contact lenses, including prosthetic, cosmetic, and visibility tints. Prosthetic tints are used to improve the appearance of a disfigured eye or help correct vision in a poorly functioning eye. Cosmetic tints are used to enhance or change eye color and come in transparent or opaque varieties. Visibility tints have a light blue or green tint to help with lens handling but do not affect eye color. Considerations for fitting and using tinted contact lenses include measuring iris diameter and determining tint requirements. Potential risks are similar to standard soft lenses and include toxic effects and corneal edema.
This document discusses several major cosmetics and personal care companies - Estee Lauder, Mary Kay, L'Oreal, and Artistry. It provides an overview of each company's history, founders, product lines, positioning, competitors, and key marketing strategies. For Estee Lauder, it describes founder Estee Lauder's background and philosophy of direct marketing and focusing on high-end department stores. For Mary Kay, it outlines the company's product promises around safety, innovation, and customer satisfaction. And for L'Oreal, it notes the company's global scale and focus on celebrity brand ambassadors and social responsibility initiatives.
Sales Management - Bausch & Lomb Presentationminneapplealex
John Hardy, Alex Heide, Ross Gregerson & Laura Grbavcich presented on Bausch & Lomb's business portfolio and market overview. Bausch & Lomb has 12,000 employees servicing over 100 countries and was founded in 1853. Their customer base includes optometrists, ophthalmologists, and retailers. They sell lens brands, cleaning solutions, and pharmaceuticals. The presentation discussed restructuring their sales force to identify cross-selling opportunities and target larger accounts to leverage their full product line.
This document summarizes Microbix's annual general meeting for 2012. Key points include exiting 2012 as cash flow positive by closing a Kinlytic agreement, funding LumiSort development, relocating the VIRUSMAX joint venture, and growing virology profits. It also provides financial projections showing Kinlytic generating $100 million in revenue by year 3 and $400 million by year 5, and an overall gross sales target of $240 million across business segments by 2016.
Slide deck for finance lecture of MSKCC (NYC) Biomedical Science Leadership course. May 2016.
https://www.eventbrite.com/e/leadership-for-scientists-tickets-21213494132
2015 deep research report on global optically functional films and coatings i...Research Hub
This document provides an in-depth research report on the global optically functional films and coatings industry for displays. It includes an overview of the industry, analysis of international and China markets, technical data on manufacturing plants, production by region and technology, profiles of key manufacturers, and forecasts for 2015-2020. The report finds that the industry has grown significantly due to increasing demand for displays and provides detailed information on market size, trends, major players, and the outlook for the future.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
Annual State of Clinical Development CostsTTC, llc
The document summarizes key findings from a survey and presentation on annual clinical development costs. It discusses how:
1) Drug development costs are increasing while productivity is declining, putting pressure on the traditional development model.
2) Cost management strategies being used by companies include greater use of CROs, new geographic sites, and standard of care payments to reduce sponsor costs while increasing site payments.
3) Survey findings show CRO costs have risen significantly in recent years and continue to increase, while costs are lower in new geographic sites like Eastern Europe, Asia, and Latin America.
Ws from innovation to commercialisation marcel van der sluisIventus
Presentation of dr. Marcel van der Sluis, Manager BD Drug Development Cluster at the Workshop 'From Innovation to Commercialisation' during the Dutch Life Sciences & Health Conference 2010
- The document discusses PositiveID's molecular diagnostic technologies for infectious disease detection, including its M-BAND and Firefly Dx products. It highlights PositiveID's recent acquisitions of E-N-G Mobile Systems and Caregiver thermometers, which provide synergies across technology platforms and add revenue.
- Financial details are provided, showing $2.9 million in revenue for 2015 and $1.7 million for Q1 2016. The company projects 2016 revenues of $5-6 million.
- Key markets for PositiveID's products include biological detection, point-of-need testing, food safety testing, and medical devices, with total addressable markets in the billions. Commercialization of Firefly D
Bayer Environmental Science discusses innovation through formulation technology. They highlight the need for continuous innovation to stay ahead of competition and changing regulations. Bayer uses formulation technology to improve existing chemistries and develop new product concepts. Their innovation strategy includes long-term goals of new modes of action, mid-term goals of improving product features through formulation advances, and short-term goals of updating their portfolio. Examples provided are long-lasting vector control products and a wash-off resistant perimeter treatment. Their new Suspend Flexx product uses solid particle technology to improve performance on rough surfaces.
The document discusses trends in the biosimilars industry and what the future may hold. It notes that while biosimilars were initially thought to be easily developed and able to capture large portions of biologic drug markets, development has proven more difficult than expected. Margins for both biosimilar and originator companies are expected to decrease significantly as the biosimilars industry mirrors the small molecule generic drug industry with intense price competition. Supporting industries like disposable technology manufacturers may see rising profits and market share. Overall, the biosimilars industry is predicted to face many of the same competitive pressures as the generic drug market.
Innovega is developing a transformative eyewear system called eMacula that combines smart contact lenses and stylish glasses. The system will provide unprecedented assistance to the 15 million visually impaired through magnification and enhancement of the wearer's vision. It will also open new mass consumer markets by offering normal, stylish glasses that provide augmented and virtual reality experiences. Innovega has assembled a team with experience from Microsoft, Sony, and Bausch + Lomb and has investors including Tencent. Clinical trials are underway and FDA approval is being pursued to bring the innovative product to market.
Gs503 vcf lecture 7 innovation finance i 300315Stephen Ong
This document discusses financing innovation through R&D and the use of Monte Carlo simulation and real options analysis. It begins by looking at typical sources of R&D funding in the US and definitions of basic research, applied research, and development. It then discusses challenges in financing long-term projects like pharmaceutical R&D. Strategic alliances and licensing are presented as major sources of funding for small biotech companies. The document introduces tools like event trees, decision trees, and Monte Carlo simulation that can be used to evaluate projects with uncertainty. It explains how these tools relate to venture capital valuation of companies with significant R&D components.
PositiveID is developing innovative molecular diagnostic technologies for biological testing and detection, including its Firefly Dx platform for rapid, point-of-need testing. Recent acquisitions of E-N-G, specializing in mobile labs, and Caregiver, an FDA-cleared thermometer, provide synergistic products and revenue. PositiveID reported $2.9 million in revenue for 2015 and $4.6 million for the first nine months of 2016, projecting $5-6 million for full-year 2016. Firefly Dx targets large molecular diagnostics markets and could begin commercial sales in 2017-2018 following field testing.
This document discusses how simulation can be used to model real-world risk in biopharma portfolio optimization. It notes that traditional approaches using expected net present value alone are insufficient. Simulation allows modeling of uncertain variables like clinical trial outcomes, development timelines, and commercial performance. This provides a statistical view of portfolio outcomes over many iterations. It enables analysis of key metrics like the probability of meeting revenue or launch targets. Simulation also facilitates sophisticated tradeoff analysis by characterizing portfolio risk-return and evaluating how changes, like adding new programs, impact overall performance and risk levels.
The Indian pharmaceutical industry has grown significantly over the past few decades. It now supplies over 50% of global demand for various vaccines and over 40% of generic demand in the US. The industry is expected to reach $20-23 billion by 2015, growing at 8-9% annually. Key strengths that have enabled this growth include low manufacturing costs, a large skilled workforce, and a strong domestic market. However, the industry still lags in innovation and must invest more in research to compete globally.
This document provides instructions for applying makeup. It begins by explaining how makeup can highlight one's natural features and make the face more attractive. It then discusses factors to consider like skin tone, eye color, and hair color when choosing shades. Warm and cool colors are introduced. Steps are outlined for determining skin undertone and complementary colors before selecting eye, cheek, and lip colors. Specific makeup products and tools are named. Detailed instructions are given for the application process and cleanup. The goal is to choose flattering shades and apply makeup to subtly enhance one's natural beauty.
This document provides an overview of business policy and strategic management. It defines strategic management as analytical thinking and commitment of resources to action aimed at ensuring organizational objectives are achieved. The document outlines the strategic management process, including developing a corporate vision and mission, and operating strategies at different organizational levels. It also defines strategy as a long-range plan to achieve an organization's goals and position itself competitively. Finally, the document discusses how strategic management helps organizations adapt to changing business environments through strategic planning.
The document summarizes information about five French companies - ABC Texture, Agrimer, BeautyMed, Lessonia, and TechNature - exhibiting at the Beautyworld Middle East trade show. It also provides details about Bretagne Commerce International, a non-profit organization assisting Breton companies in international business. The exhibitors showcase cosmetics, natural products, and professional equipment from France's Brittany region, known for its marine resources, cosmetics industry, and support for foreign investment.
The document discusses the Global Corporate Reputation Index, which evaluates the reputations of over 6,000 companies based on consumer surveys in 6 countries. It finds that while performance scores are higher than citizenship scores, companies with strong reputations excel at both. Tech companies have the best reputations overall, while oil and gas score lowest. China has the strongest company reputations, while Japan and Brazil are most critical. Long-standing companies tend to have stronger, more durable reputations. The top 25 companies are revealed.
Glossy Make Up is a unique lash brand with a range of inspiring false lashes for makeup artists and lash-lovers. Sophisticated designs to accentuate makeup.
This document discusses different types of tinted contact lenses, including prosthetic, cosmetic, and visibility tints. Prosthetic tints are used to improve the appearance of a disfigured eye or help correct vision in a poorly functioning eye. Cosmetic tints are used to enhance or change eye color and come in transparent or opaque varieties. Visibility tints have a light blue or green tint to help with lens handling but do not affect eye color. Considerations for fitting and using tinted contact lenses include measuring iris diameter and determining tint requirements. Potential risks are similar to standard soft lenses and include toxic effects and corneal edema.
This document discusses several major cosmetics and personal care companies - Estee Lauder, Mary Kay, L'Oreal, and Artistry. It provides an overview of each company's history, founders, product lines, positioning, competitors, and key marketing strategies. For Estee Lauder, it describes founder Estee Lauder's background and philosophy of direct marketing and focusing on high-end department stores. For Mary Kay, it outlines the company's product promises around safety, innovation, and customer satisfaction. And for L'Oreal, it notes the company's global scale and focus on celebrity brand ambassadors and social responsibility initiatives.
Sales Management - Bausch & Lomb Presentationminneapplealex
John Hardy, Alex Heide, Ross Gregerson & Laura Grbavcich presented on Bausch & Lomb's business portfolio and market overview. Bausch & Lomb has 12,000 employees servicing over 100 countries and was founded in 1853. Their customer base includes optometrists, ophthalmologists, and retailers. They sell lens brands, cleaning solutions, and pharmaceuticals. The presentation discussed restructuring their sales force to identify cross-selling opportunities and target larger accounts to leverage their full product line.
This document summarizes Microbix's annual general meeting for 2012. Key points include exiting 2012 as cash flow positive by closing a Kinlytic agreement, funding LumiSort development, relocating the VIRUSMAX joint venture, and growing virology profits. It also provides financial projections showing Kinlytic generating $100 million in revenue by year 3 and $400 million by year 5, and an overall gross sales target of $240 million across business segments by 2016.
Slide deck for finance lecture of MSKCC (NYC) Biomedical Science Leadership course. May 2016.
https://www.eventbrite.com/e/leadership-for-scientists-tickets-21213494132
2015 deep research report on global optically functional films and coatings i...Research Hub
This document provides an in-depth research report on the global optically functional films and coatings industry for displays. It includes an overview of the industry, analysis of international and China markets, technical data on manufacturing plants, production by region and technology, profiles of key manufacturers, and forecasts for 2015-2020. The report finds that the industry has grown significantly due to increasing demand for displays and provides detailed information on market size, trends, major players, and the outlook for the future.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
Annual State of Clinical Development CostsTTC, llc
The document summarizes key findings from a survey and presentation on annual clinical development costs. It discusses how:
1) Drug development costs are increasing while productivity is declining, putting pressure on the traditional development model.
2) Cost management strategies being used by companies include greater use of CROs, new geographic sites, and standard of care payments to reduce sponsor costs while increasing site payments.
3) Survey findings show CRO costs have risen significantly in recent years and continue to increase, while costs are lower in new geographic sites like Eastern Europe, Asia, and Latin America.
Ws from innovation to commercialisation marcel van der sluisIventus
Presentation of dr. Marcel van der Sluis, Manager BD Drug Development Cluster at the Workshop 'From Innovation to Commercialisation' during the Dutch Life Sciences & Health Conference 2010
- The document discusses PositiveID's molecular diagnostic technologies for infectious disease detection, including its M-BAND and Firefly Dx products. It highlights PositiveID's recent acquisitions of E-N-G Mobile Systems and Caregiver thermometers, which provide synergies across technology platforms and add revenue.
- Financial details are provided, showing $2.9 million in revenue for 2015 and $1.7 million for Q1 2016. The company projects 2016 revenues of $5-6 million.
- Key markets for PositiveID's products include biological detection, point-of-need testing, food safety testing, and medical devices, with total addressable markets in the billions. Commercialization of Firefly D
Bayer Environmental Science discusses innovation through formulation technology. They highlight the need for continuous innovation to stay ahead of competition and changing regulations. Bayer uses formulation technology to improve existing chemistries and develop new product concepts. Their innovation strategy includes long-term goals of new modes of action, mid-term goals of improving product features through formulation advances, and short-term goals of updating their portfolio. Examples provided are long-lasting vector control products and a wash-off resistant perimeter treatment. Their new Suspend Flexx product uses solid particle technology to improve performance on rough surfaces.
The document discusses trends in the biosimilars industry and what the future may hold. It notes that while biosimilars were initially thought to be easily developed and able to capture large portions of biologic drug markets, development has proven more difficult than expected. Margins for both biosimilar and originator companies are expected to decrease significantly as the biosimilars industry mirrors the small molecule generic drug industry with intense price competition. Supporting industries like disposable technology manufacturers may see rising profits and market share. Overall, the biosimilars industry is predicted to face many of the same competitive pressures as the generic drug market.
Innovega is developing a transformative eyewear system called eMacula that combines smart contact lenses and stylish glasses. The system will provide unprecedented assistance to the 15 million visually impaired through magnification and enhancement of the wearer's vision. It will also open new mass consumer markets by offering normal, stylish glasses that provide augmented and virtual reality experiences. Innovega has assembled a team with experience from Microsoft, Sony, and Bausch + Lomb and has investors including Tencent. Clinical trials are underway and FDA approval is being pursued to bring the innovative product to market.
Gs503 vcf lecture 7 innovation finance i 300315Stephen Ong
This document discusses financing innovation through R&D and the use of Monte Carlo simulation and real options analysis. It begins by looking at typical sources of R&D funding in the US and definitions of basic research, applied research, and development. It then discusses challenges in financing long-term projects like pharmaceutical R&D. Strategic alliances and licensing are presented as major sources of funding for small biotech companies. The document introduces tools like event trees, decision trees, and Monte Carlo simulation that can be used to evaluate projects with uncertainty. It explains how these tools relate to venture capital valuation of companies with significant R&D components.
PositiveID is developing innovative molecular diagnostic technologies for biological testing and detection, including its Firefly Dx platform for rapid, point-of-need testing. Recent acquisitions of E-N-G, specializing in mobile labs, and Caregiver, an FDA-cleared thermometer, provide synergistic products and revenue. PositiveID reported $2.9 million in revenue for 2015 and $4.6 million for the first nine months of 2016, projecting $5-6 million for full-year 2016. Firefly Dx targets large molecular diagnostics markets and could begin commercial sales in 2017-2018 following field testing.
This document discusses how simulation can be used to model real-world risk in biopharma portfolio optimization. It notes that traditional approaches using expected net present value alone are insufficient. Simulation allows modeling of uncertain variables like clinical trial outcomes, development timelines, and commercial performance. This provides a statistical view of portfolio outcomes over many iterations. It enables analysis of key metrics like the probability of meeting revenue or launch targets. Simulation also facilitates sophisticated tradeoff analysis by characterizing portfolio risk-return and evaluating how changes, like adding new programs, impact overall performance and risk levels.
The Indian pharmaceutical industry has grown significantly over the past few decades. It now supplies over 50% of global demand for various vaccines and over 40% of generic demand in the US. The industry is expected to reach $20-23 billion by 2015, growing at 8-9% annually. Key strengths that have enabled this growth include low manufacturing costs, a large skilled workforce, and a strong domestic market. However, the industry still lags in innovation and must invest more in research to compete globally.
This document provides an overview of Anteo Diagnostics and their nanotechnology applications. Anteo has developed a patented nanoglue technology called Mix&Go that can bind biological molecules to synthetic surfaces. They are applying this technology in four business areas: 1) in vitro diagnostics and life sciences markets, 2) bioseparations, 3) medical devices, and 4) batteries. For each area, Anteo's nanoglue can improve functionality, sensitivity, and cost efficiency. The document outlines Anteo's revenue generation process, partnership achievements, and the vast potential of their drop-in nanotechnology.
Global Breathable Films Market PPT: Demand, Trends and Business Opportunities...IMARC Group
According to the latest report by IMARC Group,finds that the global breathable films market size reached US$ 3.33 Billion in 2021.Breathable films are cost-effective, polymer-based films that are manufactured using thermoplastic resins via extrusion technology. They provide moisture control in various products, including diapers, feminine hygiene, and incontinence protection products where breathability is an essential parameter of user comfort.
L23 cross media convergence and synergyNick Crafts
This document outlines the aims, objectives, and content for an exam lesson on cross media convergence and synergy in the contemporary film industry. It provides case study examples for students to research, such as A Field in England's multi-platform release. Key terms are defined, like cross media convergence being the ability to market and exhibit films across multiple devices. Students are assigned homework researching product placement examples and how film marketing utilizes social media. The impact of new media technologies on film consumption is discussed.
This document outlines a presentation on clinical research and development challenges and opportunities. It discusses the low productivity and increasing costs of R&D, potential loss of revenue from expiring patents, and reasons for low productivity such as target and trial design issues. It also covers trends like globalization of clinical trials to reduce costs and access large patient populations. Finally, it discusses the need for quality and qualified investigators to address the supply and demand imbalance.
This document provides an exam lesson on cross media convergence and synergy in the film industry. It discusses key concepts like how films are marketed and exhibited across multiple platforms. Students are asked to research case study examples, like how Film Four released "A Field in England" on various platforms. Product placement is explored as films make over $100 million from brands to appear on screen. Social media is highlighted as vital low-budget marketing. Overall, the lesson aims to help students understand how cross platform strategies are significant for film viewers and industry profits.
Similar to Pur vu- mock pitching presentation (20)
1. R e d e f i n i n g p r o t e c t i v e e y e w e a r.
2. IQ is...
• a start up medical device firm in the field of corrective
lenses.
• seeking exclusive rights to manufacture and commercialize
the first ever photochromic contact lenses.
• seeking capital to expand operations.
A new solution to an old problem will allow to
change the way we see world.
3. Value Proposition
P/E (Large) 17‐70
P/E (New/small) 10
P/E (Medium) 25
10x Return
5 Years
$2.0M investment
58.5% Internal Rate of
Return
$20M
Projected
EXIT
RETURN
7. Budget allocation
By key expenses
20% Manufacturing Cost ($720K)
29%
Marketing Cost ($970K)
8% Distribution and supply ($100K)
Other Operating Cost and Expenses ($210K)
39%
4% Product Registration and Clinical Study ($510K)
Estimated Total Project Cost: $2.5 million
10. The U.S. Market for Pūr‐VU®
/
YEAR 2: 0.1% OF MARKET SHARE. LA, NY
YEAR 3: 0.2% OF MARKET SHARE. LA, NY, CHICAGO
YEAR 4: 0.3% OF MARKET SHARE. LA, NY, CHICAGO, HOUSTON, PHILIDELPHIA
YEAR 5: 0.5% OF MARKET SHARE. ALL OF UNITED STATES
11. Sales Projections
EXIT
30 0.60%
25 0.50%
Target Market Share (%)
20 0.40%
Total Net Income
(USD in Millions)
15 0.30%
Product Launch
10 0.20%
5 0.10%
0 0.00%
1 2 3 4 5
Year
Market Share
Total Net Income
12. Conclusion
T h e f i rs t e v e r c o r r e c t i v e d a i l y w e a r p h o to c h ro m i c c o nta c t
l e n s m a d e u s i n g n o v e l p ate n t p ro te c te d te c h n o l o g y.
$2.0M investment
10x Return in 5 Years
EXIT $20M
Projected Return
13. C h a n g i n g t h e w ay yo u s e e t h e w o r l d .
14. C h a n g i n g t h e w ay yo u s e e t h e w o r l d .
15. C h a n g i n g t h e w ay yo u s e e t h e w o r l d .
18. Regulatory Pathway
Class II Medical Device
Premarket Notification
Application (510K)
Investigational device
exemption application (IDE)
Clinical Performance Study
19. Clinical Performance Study
3 months randomized study
Test Lenses
(Pūr‐VU)
Five Independent
50 Test Subjects
Investigators
Control Lenses
(Predicate Lenses)
Predicate 1‐Day Acuvue (Johnson & Johnson)
Devices Dailies AquaConformt (CIBA Vision)
Soflens Daily Disposable (Bausch & Lomb)
24. Competitor Analysis
The Porter Five Model
Substitutes Buyer Power
Medium risk of being substituted High buyer power
Three of the four competitors have substitutes available Bias in prescribing behaviour based on brand
(Vistakon, Inc., CIBA Vision, and Bausch & Lomb). preferences
Supplier Power Potential Entrants
Strong supplier power Low‐Medium Entry Barrier
Pūr-vu contact lenses are two‐in‐one: they provide Medium start‐up cost
vision correction and sun protection Requires licensure of patented and proprietary
Ability to transition in under 20 seconds from technology
transparent to tinted contact lenses, and vice versa
Internal Rivalry
High intensity
Competitors’ products are medicore substitute to Pūr-VU contact lenses.
25. Competitor Analysis
SWOT Analysis
Strength
• Prescription lens – improve vision
• Non prescription lens – everyone can use them Opportunity
• Don’t require additional sun protection – other • Bringing the product to the US market will require
accessories, such as sunglasses are not needed partnership with a large pharmaceutical company
• Specific protection – receive protection depending
on the level of UV light • Once customer base is established, can sell the
• Cost saving – 2‐in‐1 contact lenses act to correct business off a pharmaceutical company
vision and provide UV protection
• Patented technology Threat
• Novel material improved oxygen permeability and
moisture content • Threat of current substitutes in the market
• Entry of other competitors into the market
Weakness • Medical device product life cycles tend to be shorter
• Inadequate sun protection in vehicles – the glass
inside a car may block UV light, and thus the level of
brightness is minimized even though exposure to
UV light is occurring
26. Competitor Analysis
List of Competitors
Competitors Soft Contact Competitive product
Market Share in the
U.S. (2009)
Vistakon , Inc. 46% Acuvue ‐ provide UV protection with
(Johnson & Johnson) absorption of up to 82% of UV‐A radiation,
and up to 97% of UV‐B radiation.17
CIBA Vision 24% Precision UV® ‐ absorbs up to 90% of harmful
(Novartis) UV radiation.18
CooperVision, Inc. 17% ‐
Bausch & Lomb, Inc. 12% ‐
Nike Nike’s MaxSight Contacts – comes in two
‐ shades: grey‐green for sports played in bright
light and amber for sports that are fast
paced.19